Tyra Biosciences (NASDAQ:TYRA) Rating Increased to Hold at Wall Street Zen

Tyra Biosciences (NASDAQ:TYRA) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other analysts also recently issued reports on TYRA. Oppenheimer reiterated an “outperform” rating and issued a $36.00 price target on shares of Tyra Biosciences in a report on Wednesday, September 10th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, August 22nd. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Thursday, November 6th. Raymond James Financial started coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Tyra Biosciences Price Performance

NASDAQ TYRA opened at $21.50 on Friday. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $22.83. The firm has a market capitalization of $1.15 billion, a P/E ratio of -11.50 and a beta of 1.09. The business’s 50-day simple moving average is $16.31 and its 200-day simple moving average is $12.73.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). On average, equities research analysts expect that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of Tyra Biosciences stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the sale, the director directly owned 3,833,425 shares in the company, valued at $77,626,856.25. The trade was a 6.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.20% of the stock is currently owned by company insiders.

Institutional Trading of Tyra Biosciences

A number of hedge funds have recently made changes to their positions in TYRA. Jacobs Levy Equity Management Inc. boosted its stake in Tyra Biosciences by 23.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 301,801 shares of the company’s stock valued at $2,807,000 after acquiring an additional 57,556 shares during the last quarter. Polar Asset Management Partners Inc. increased its position in shares of Tyra Biosciences by 27.1% in the 1st quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company’s stock worth $1,314,000 after purchasing an additional 30,134 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Tyra Biosciences in the 1st quarter valued at about $465,000. Corton Capital Inc. bought a new position in shares of Tyra Biosciences during the second quarter worth about $233,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Tyra Biosciences in the second quarter worth about $177,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.